Antibody Structure and Function

An antibody (immunoglobulin, Ig) is a Y-shaped glycoprotein secreted by plasma cells, built from four polypeptide chains: two identical heavy chains (~50 kDa each) and two identical light chains (~25 kDa each), linked by disulfide bonds into a symmetric dimer of heterodimers. Each chain is organized into repeating globular units called immunoglobulin domains, each roughly 110 amino acids and stabilized by an internal disulfide bond that locks a characteristic sandwich of two beta sheets — the immunoglobulin fold. Light chains contain one variable domain (V_L) and one constant domain (C_L); heavy chains contain one variable domain (V_H) followed by three or four constant domains (C_H1, C_H2, C_H3, sometimes C_H4), depending on isotype. The N-terminal V_H and V_L domains pair up to form the antigen-binding site, and within them, three short hypervariable loops per chain — the complementarity-determining regions (CDRs), especially CDR3 — make direct contact with the epitope. Everything downstream of the variable domains is constant within an individual's antibody repertoire for a given isotype, meaning it does not vary with antigen specificity; this constant region is what the immune system uses to decide what to do once binding has occurred. This structural split is functional as much as it is physical: proteolytic digestion of an antibody with papain cleaves it into two identical Fab fragments ("fragment antigen-binding," each containing one V_H-C_H1 paired with one V_L-C_L) plus one Fc fragment ("fragment crystallizable," the paired C_H2-C_H3 domains, so named because it crystallized readily in early biochemical purifications). Fab retains antigen-binding activity; Fc retains no antigen specificity but carries all of the antibody's effector activity — the ability to fix complement, bind Fc receptors on immune cells, cross the placenta, or dimerize into secretory forms.

Step 1: Domain architecture creates a rigid recognition scaffold. Each immunoglobulin domain folds into two antiparallel beta sheets connected by a conserved intradomain disulfide bond, forming a compact beta-barrel-like sandwich roughly 4 nm across. This fold is so structurally efficient that it is reused throughout the immune system — in T-cell receptors, MHC molecules, and many cell-adhesion proteins — collectively called the immunoglobulin superfamily. In the variable domains, three loops per chain (CDR1, CDR2, CDR3) sit at one edge of the sandwich; because V_H and V_L pair face to face, their six CDR loops (three from each chain) converge to form one continuous, antigen-contoured surface at the tip of each arm.

Step 2: Hinge flexibility lets the two arms move independently. Between C_H1 and C_H2, most heavy chains have a proline- and cysteine-rich hinge region that lacks the compact Ig-fold and is instead extended and flexible. This hinge lets the two Fab arms swing relative to each other and relative to the Fc stalk, so that a single antibody molecule can bind two epitopes separated by variable distances — critical for cross-linking antigens on a bacterial surface or on adjacent viral particles. IgM and IgE lack a classical proline hinge but instead have an extra constant domain (C_H4/C_H3-equivalent) that provides some flexibility; IgG3 has an unusually long hinge (up to ~62 residues) making it the most flexible IgG subclass, and correspondingly the most efficient at complement fixation.

Step 3: Two disulfide-bonded light chains and two heavy chains assemble into the basic unit. Interchain disulfide bonds link each light chain to its heavy chain (near C_L–C_H1) and link the two heavy chains together at the hinge, producing the four-chain Y. Light chains come in two types, kappa (κ) and lambda (λ), encoded by separate loci; a given antibody uses one or the other but never both, and in humans roughly 60% of antibodies use κ and 40% use λ (this κ:λ ratio is clinically useful — a skewed ratio in a patient's serum or biopsy suggests a monoclonal, potentially malignant, B-cell population).

Step 4: The Fc region recruits the effector machinery. Once the Fab arms have bound antigen, the Fc region — normally somewhat "hidden" in the unbound antibody — becomes accessible and can engage two classes of partners: 1. Complement protein C1q, which binds clustered Fc regions (best on IgM and IgG1/IgG3) once antibody is bound to a multivalent antigen (like a bacterial surface), triggering the classical complement cascade, opsonization (C3b deposition), and eventually membrane attack complex formation. 2. Fc receptors (FcR) on phagocytes (FcγR on macrophages and neutrophils, FcαR on neutrophils, FcεRI on mast cells and basophils) and on NK cells (FcγRIII/CD16), which trigger phagocytosis of opsonized microbes, antibody-dependent cellular cytotoxicity (ADCC), or mast cell degranulation, respectively. Antigen binding at the Fab tip and effector engagement at the Fc stalk are physically separated by ~14–15 nm, but functionally coupled: an unbound antibody rarely fixes complement or clusters Fc receptors efficiently, because engagement requires either conformational change or simply the local antigen-driven clustering of many antibody molecules (and hence many Fc regions) on a single microbial surface. This is why free serum antibody does not spontaneously trigger inflammation — the effector functions are context-dependent on antigen engagement, not autonomous properties of the Fc region alone.

Step 5: The heavy-chain constant region defines the isotype and its specialized biology. Class switching (isotype switching), covered in more depth alongside Antibody Diversity and VDJ Recombination, allows a B cell to keep the same antigen specificity (same V_H/V_L, same CDRs) while changing which constant-region gene segment (Cμ, Cδ, Cγ, Cε, or Cα) is spliced onto it, thereby changing the isotype and its effector profile without altering what antigen is recognized.

IgM is secreted as a pentamer (five monomeric units joined by a small polypeptide called the J chain and disulfide bonds), giving it 10 antigen-binding sites total — enormous avidity that compensates for the comparatively low intrinsic affinity of early, unmutated antibodies. Secretory IgA is typically a dimer, also joined by J chain, and additionally carries a secretory component — a fragment of the poly-Ig receptor that remains attached after transcytosis across mucosal epithelial cells, protecting IgA from degradation by mucosal proteases.

The four-chain, Fab/Fc model was not assumed; it was built from a sequence of biochemical experiments in the 1950s–60s, later confirmed by crystallography.

Rodney Porter's proteolytic dissection (1959). Porter treated rabbit IgG with the plant protease papain, which cleaves the heavy chain just above the interchain disulfide bonds in the hinge. The digest yielded three fragments of similar size (~45 kDa each), separable by ion-exchange chromatography. Two of the three fragments retained the ability to bind antigen but could not precipitate it (because each had only one binding site) — Porter named these Fab (fragment, antigen-binding). The third fragment could not bind antigen at all but crystallized readily in cold storage — he called it Fc (fragment, crystallizable). This single result established that the antibody molecule is functionally bipartite: two identical antigen-binding units plus one distinct, non-binding unit. Porter then used pepsin, which cleaves below the interchain disulfide bonds (rather than above, as papain does), producing a single divalent fragment, F(ab′)₂, that retained the ability to cross-link and precipitate antigen, plus small peptide fragments of Fc that were degraded further — showing that divalency (two binding arms held together) was necessary for antigen precipitation/agglutination, while the Fc region was dispensable for binding but essential for effector activity.

Gerald Edelman's chain-separation chemistry (early-to-mid 1960s). Working in parallel, Edelman used reducing agents (to break interchain disulfide bonds) combined with denaturants (to disrupt noncovalent chain association) followed by gel filtration, to physically separate IgG into its heavy and light polypeptide chains and determine their independent molecular weights (~50 kDa and ~25 kDa respectively) — confirming that the four-chain (2 heavy + 2 light) model, rather than a single polypeptide, was correct, and that heavy and light chains each contribute to antigen binding. Edelman went on to determine the complete amino acid sequence of an entire immunoglobulin molecule (a landmark of protein chemistry given its ~1,300 residues across four chains), directly revealing the internally repeated ~110-residue domains and the sharp variable/constant boundary within each chain — the first direct sequence evidence for the V/C domain organization. Porter and Edelman shared the 1972 Nobel Prize in Physiology or Medicine for this combined structural work.

X-ray crystallography (late 1960s–1970s). Structures of Fab fragments and later intact IgG molecules (notably by David Davies, Roberto Poljak, and colleagues) confirmed at atomic resolution what proteolysis and sequencing had inferred: the immunoglobulin fold, the pairing of V_H with V_L and C_H1 with C_L, the location of the hypervariable loops exactly at the tip of the combining site, and the flexible, extended hinge — visually validating the two-dimensional domain map with a real three-dimensional structure.

Why this evidence matters pedagogically. Each experiment isolated one structural claim and tested it independently: papain proved bipartite function (Fab vs Fc), pepsin proved divalency is required for precipitation, reduction/alkylation proved the two-chain-type composition, sequencing proved the domain repeat and V/C boundary, and crystallography proved 3-D geometry. No single experiment "discovered" the antibody structure — the model survived because independent methods converged on the same answer.

Example 1 — Reading an isotype-switch time course (serology problem). A patient is exposed to a novel bacterial polysaccharide antigen for the first time (a primary immune response). Serum antibody titers against the antigen are measured by ELISA at days 0, 5, 10, 14, and 21.

Reasoning: IgM appears first (by day 5) because naive B cells initially express and secrete only IgM/IgD without needing class-switch recombination — the μ constant-region gene is the default. Peak IgM occurs around day 10, then declines. IgG rises later (first detectable ~day 10, exceeding IgM by day 14) as class switching (isotype switching to Cγ, driven by T-cell help and cytokines) and affinity maturation proceed in germinal centers. By day 21, IgG dominates and IgM has waned — the classic primary-response signature. Diagnostically, high IgM with low/absent IgG against a pathogen indicates a recent, acute infection; high IgG with low IgM indicates past infection or immunity (from prior exposure or vaccination) — this logic underlies TORCH panels in prenatal screening and many infectious-disease serologies.

Example 2 — Calculating the theoretical avidity advantage of IgM over IgG. Suppose a monomeric IgG antibody binds a single epitope on a bacterial surface with an intrinsic (per-site) dissociation constant K_D = 10⁻⁶ M (relatively low affinity, as might occur early after immunization). A pentameric IgM antibody, made from B cells recognizing the same epitope with the same per-site affinity (K_D = 10⁻⁶ M per site), has up to 10 potential binding sites, but on a rigid, repetitive bacterial surface, geometric constraints typically allow simultaneous engagement of only some subset (empirically, often 5 of the 10 sites can engage a flat repetitive array at once due to the pentamer's planar/staple conformation). Reasoning: For multivalent binding, overall avidity increases roughly multiplicatively with the number of simultaneously engaged sites because all bonds must break at once for the antibody to dissociate — a phenomenon sometimes called the "avidity effect" or "chelate effect." While a precise thermodynamic avidity constant requires cooperative binding models beyond simple multiplication, the qualitative conclusion holds and is well-supported experimentally: functional (avidity) affinity of pentameric IgM for repetitive antigen is commonly 3–4 orders of magnitude tighter than the same antibody's intrinsic monovalent K_D, even though IgM's raw per-site affinity is usually lower than a mutated, affinity-matured IgG. This explains why IgM, despite having undergone no somatic hypermutation, is nonetheless an effective early defense: it compensates low per-site affinity with high valency (avidity), while later-arising IgG compensates lower valency (2 sites) with much higher per-site affinity from affinity maturation — two different structural strategies converging on effective pathogen binding.

Diagnostics. IgM-versus-IgG serology (as in Example 1) distinguishes acute from past infection in tests for hepatitis, rubella, toxoplasmosis, and, more recently, SARS-CoV-2. ELISA and lateral-flow rapid tests exploit isotype-specific secondary antibodies (anti-human-IgM vs anti-human-IgG) that themselves target Fc-region epitopes unique to each isotype.

Monoclonal antibody therapeutics. Drugs like trastuzumab (breast cancer), rituximab (lymphoma/autoimmune disease), and adalimumab (rheumatoid arthritis) are engineered IgG molecules whose Fab specificity is chosen for a disease target, while the IgG1 Fc region is often deliberately retained (or engineered) to trigger ADCC and complement-mediated killing of the target cell — directly exploiting the modular Fab/Fc logic described here. Fc-engineering (mutations that increase or decrease FcγR or C1q binding) is now a major axis of antibody drug design, allowing scientists to "silence" Fc effector function when only blocking is desired, or enhance it when killing the target cell is the goal.

Antibody fragments as tools and drugs. Fab fragments (e.g., ranibizumab for macular degeneration) and single-chain variable fragments (scFv) are used when Fc-mediated effector function or long serum half-life is undesirable — the Fab/Fc separation Porter discovered is now routinely engineered rather than merely observed.

Neonatal immunity. The IgG-specific neonatal Fc receptor (FcRn) actively transports maternal IgG across the placenta, giving newborns passive immunity that wanes over the first months of life — explaining both the protective window before an infant's own antibody repertoire matures and the rationale for maternal vaccination (e.g., pertussis, influenza) during pregnancy.

Mucosal and allergic disease. Secretory IgA deficiency, the most common primary immunodeficiency, causes recurrent sinopulmonary and gastrointestinal infections, illustrating the isotype's non-redundant mucosal role. Anti-IgE monoclonal therapy (omalizumab) treats severe allergic asthma by sequestering free IgE before it can bind FcεRI, directly targeting the isotype-specific effector mechanism described above.

Agriculture and conservation. Antibody-based diagnostics (isotype-specific ELISAs) are used to screen livestock for brucellosis and bovine tuberculosis and to monitor pathogen exposure in wildlife populations, where IgM/IgG ratios help estimate whether an outbreak is recent or historical in a herd or population.

Ask the tutor: How does somatic hypermutation during affinity maturation actually reshape the CDR loops to increase antibody affinity, and how is this tested experimentally?